

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Directors**”) of Wai Chun Bio-Technology Limited (the “**Company**”) announces that (i) Ms. LI Huifang (“**Ms. LI**”) has tendered her resignation as the company secretary of the Company (the “**Company Secretary**”) and has ceased to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 28 March 2024; and (ii) Mr. Lam Kai Kei (“**Mr. Lam**”) has been appointed as the Company Secretary and Authorised Representative with effect from 28 March 2024.

Ms. LI has confirmed that she has no disagreement with the Board and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Mr. Lam, aged 38, holds a master’s degree in corporate governance from The Hong Kong Polytechnic University and a Bachelor of Commerce (Honours) in Accounting from Hong Kong Shue Yan University. Mr. Lam is a fellow certified practising accountant of CPA Australia and an associate member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

Mr. Lam has more than 15 years of experience in corporate governance, corporate finance, auditing and financial management. Mr. Lam is currently a financial controller of Renaissance Asia Silk Road Group Limited, the issued shares of which are listed on the Main Board of the Stock Exchange (stock code: 274). Mr. Lam was an accounting manager of Sino-Ocean Group Holding Limited, the issued shares of which are listed on the Main Board of the Stock Exchange (stock code: 3377) from December 2021 to October 2022. He also served as finance manager of China Vast Industrial Urban Development Company Limited, the issued shares of which are listed on the Main Board of the Stock Exchange (stock code: 6166) from December 2017 to December 2021. Prior to joining the listed companies, he mainly worked in two international audit firms for over 7 years. The Board is of the view that Mr. Lam is qualified to act as the company secretary under Rule 3.28 of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to take this opportunity to express its sincere gratitude to Ms. LI for her contribution to the Company during her tenure of service and also extend a warm welcome to Mr. Lam on his new appointment.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ka Chun
Executive Director

Hong Kong, 28 March 2024

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer) and two independent non-executive Directors, namely and Ms. Hong Ting and Mr. Wan Bo.